Treatment on HBeAg Positive or HBeAg Negative in Chronic Hepatitis B

• Status: Approved for marketing
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Phyllanthus Urinaria - Adenosma Glutinosum - Eclipta Prostrata - Ascorbic Acid combination plus Tenofovir in treatment of acute and chronic hepatitis B. Method the combination of drugs derived from natural and artificial medicaments.

Has stronger effect on immune system, effective good against HBV replication. This is a substantial new insight into the pathogenesis of disease, with a clear path toward clinical application, or which would lead to a substantial advance and perfect in management or public health policy.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nguyen Thi Trieu, MD; Triệu, Nguyễn Thị, M.D.
• Treatments: Ascorbic Acid; Tenofovir

Criteria

Inclusion Criteria:

Inclusion Criteria:

• Males and females ≥ 18 years of age with chronic and acute hepatitis B.

• Hepatitis B surface antigen (HBsAg)(+) for a minimum of 6 months prior to entry.

• Hepatitis B envelope antigen (HBeAg)(+) or (-) at baseline.

• Patients having treated or untreated

• Patients with compensated liver function (Child-Pugh score ≤ 6).

• Informed writted consent.

Exclusion Criteria:

• Any serious or active medical or psychiatric illness which, in the opinion of the investigator, would interfere with patient treatment, assessment or compliance with the protocol. or cytokine-based therapies with possible activity in hepatitis B disease within 6 months prior to study screening.

• Organ or bone marrow transplant recipients.

• Evidence of active liver disease to operate.

• Received immunoglobulins, interferon or other immune e to other causes (e.g., Wilson's disease, hemochromatosis, autoimmune hepatitis, hepatitis C, hepatitis D or HIV.)

• Patients taking parenteral (intravenous or intramuscular or subcutaneous) or oral steroids, immuno-suppressant therapies or chemotherapeutic agents within 2 months of study screening or expected to receive these agents during the course of the study.

• Clinically relevant alcohol or drug use or history of alcohol or drug use considered by the investigator to be sufficient to hinder compliance with treatment, follow up procedures or evaluation of adverse events.

• Hepatocellular carcinoma.

• Serious concurrent medical illness other than hepatitis B.

• History of hypersensitivity to nucleoside analogues.

• Women of childbearing potential not practising adequate contraception.

• Pregnancy or lactation.